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Recombinant human thrombomodulin
inhibits neutrophil extracellular trap
formation in vitro
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Abstract
The aim of this study was to investigate the effects of recombinant human-soluble thrombomodulin (rTM) on
lipopolysaccharide (LPS)-induced, platelet-dependent neutrophil extracellular trap (NET) formation (NETosis). Human
peripheral blood neutrophils and platelets were co-incubated with or without LPS (0.2 μg/ml) in the presence and
absence of rTM (2 μg/ml). NETosis was confirmed by immunostaining and confocal microscopy. In the absence of
platelets, LPS did not induce NETosis in the neutrophils. NETosis, however, was induced by LPS when neutrophils
were co-cultured with platelets (64 % of neutrophils). Notably, rTM was able to fully inhibit NETosis in neutrophils
cultured with platelets and in the presence of LPS. rTM did not induce NETosis in this co-culture system (p < 0.01
versus LPS in the absence of rTM). These results show that rTM can suppress LPS-induced platelet-dependent
NETosis in vitro.
Keywords: Disseminated intravascular coagulation, Innate immunity, Neutrophil extracellular traps, Sepsis,
Thrombomodulin
Introduction
Neutrophil extracellular traps (NETs) are important for
local defense against invading pathogens [1]. However,
NET formation, also known as NETosis, can cause or
exacerbate hypercoagulability, microvascular thrombosis,
and vascular endothelial dysfunction in critical illness,
including sepsis [2].
Thrombomodulin (TM) is mainly expressed on the
cell surface of endothelial cells, but the soluble form of
TM also exists in the circulation [3]. TM exerts protective
effects against endothelial dysfunction and damage
associated with sepsis and coagulopathy [4]. However,
the mechanisms underlying the protective effects of
TM in endothelial cells are not completely understood.
Recently, recombinant human-soluble TM (rTM) has
been used for the treatment of patients with sepsis-associ-
ated disseminated intravascular coagulation (DIC) in
Japan, and rTM treatment has shown protective ef-
fects [5].
A previous study demonstrated that lipopolysaccharide
(LPS) induces NET formation in a platelet-dependent
manner [2]. Consistent with this previous study, we
found that while neither LPS nor platelets alone caused
NETosis in cultured neutrophils, LPS co-cultured with
neutrophils and platelets markedly induced NETosis.
These results clearly indicate that LPS-induced NET
formation is platelet-dependent.
We noticed that NET formation induced by both LPS
and activated platelets resembled a serious condition of
inflammation in response to infection, such as during
septic shock and sepsis-associated DIC. However, the
effects of rTM on NET formation have not been studied.
Therefore, in this study, we investigated the effects of
rTM on NETosis in the presence of both LPS and plate-
lets in vitro.
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Methods
Isolation of human neutrophils and platelets
Peripheral blood was collected in EDTA-containing
Vacutainers from ten healthy volunteers. Neutrophils
were isolated using Polymorphprep (Axis-Shield, Dundee,
UK). For platelet isolation, 2 ml of whole blood containing
3.2 % sodium citrate solution was centrifuged at 300 g for
5 min at 4 °C. Platelet-rich plasma was centrifuged at
1000 g for 15 min at 4 °C, the supernatants were re-
moved, and the cell pellets were resuspended in PBS.
In vitro NET formation
In vitro NETosis was induced as previously described [6]
with minor modifications. In brief, neutrophils (5 × 104)
were incubated in PBS containing 10 % fetal bovine
serum with or without platelets (5 × 105). LPS (Escheri-
chia coli 0111, 125-05201, Wako Pure Chemical Indus-
tries, Ltd., Osaka, Japan) was added at 0.2 μg/ml to
stimulate cells. To investigate the effect of rTM on the in-
hibition of NETosis, incubated cells were treated with rTM
(2, 10, or 50 μg/ml (39, 192, or 960 nM), ART-123,
a) b)
c) d)
e) f)
Fig. 1 Inhibition of LPS-stimulated platelet-dependent NETosis by rTM. Neutrophils (5 × 104) and platelets (5 × 105) from the same individuals were
resuspended in 100 μl of PBS containing 10 % fetal bovine serum. Cultured cells (neutrophils alone or with platelets) were incubated with or without
LPS (0.2 μg/ml) in the presence or absence of rTM (2 μg/ml). Immunostaining for MPO and histone H2A.X was performed, and nuclei were stained
with DAPI. a–d Normal neutrophils were cultures alone (a), with LPS alone (b), with platelets alone (c), or co-cultured with platelets and LPS (d).
e–f rTM was added to the co-culture of neutrophils and platelets with (e) or without LPS (f). Arrows indicate neutrophils that underwent NETosis. Blue,
DAPI; green, MPO; red, histone H2A.X; yellow, merged signals. Magnification: ×63, scale bar = 10 μm
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provided by Asahi Kasei Pharma Corp., Tokyo, Japan)
immediately after LPS stimulation and incubated for
30 min at 37 °C in 5 % CO2. rTM concentrations were
chosen based on previous studies [7, 8]. Clinically, rTM
(0.06 mg/kg) was administered intravenously once daily for
six consecutive days, and Cmax (maximum plasma drug
concentration) reached 1600 ng/ml [7]. Furthermore, pre-
vious studies used rTM concentrations of 2 or 20 μg/ml in
vitro [8]. Therefore, rTM was added at the concentrations
of 2, 10, or 50 μg/ml in this study.
Immunostaining and confocal microscopy
Cells were stained with an anti-myeloperoxidase (MPO)
(ab45977, Abcam, Cambridge, MA, USA) or histone
H2A.X antibody (sc-54607, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), followed by species-specific second-
ary antibodies conjugated with Alexa Fluor Dyes (Invitro-
gen, Life Technologies Japan, Tokyo, Japan). DNA was
stained with DAPI (D1306, Invitrogen, Life Technologies).
NETosis was evaluated by the release of MPO, histone
H2A.X, and DNA from the neutrophils using a confocal
microscope (LSM 710 confocal microscope; Carl Zeiss
MicroImaging, Jena, Germany). The numbers of NETs and
total neutrophils were counted, and the percentage of NETs
in the total neutrophils was calculated as previously
described [9, 10].
Statistical analyses
The percentage of NETs was expressed as median with
interquartile range (IQR) and compared using the
Kruskal-Wallis one-way analysis of variance on ranks.
Results
The number of neutrophils was counted in the observa-
tion view field of a microscope image.
LPS did not induce NETosis when neutrophils were
not co-cultured with platelets. Without LPS stimulation,
NETosis did not occur in the co-culture of neutrophils
and platelets (Fig. 1a–c). However, when neutrophils
cultured in the presence of platelets were stimulated by
LPS, neutrophils released chromatin (observed by
histone H2A.X staining) lined with granular components
(observed by MPO staining), creating fibrous nets in the
cytoplasm. These observations confirmed that neutro-
phils emitted NETs (Fig. 1d). This confirms previous
observations showing that the NETosis induced by LSP
is platelet-dependent [2].
To investigate the effect of rTM on LPS-induced
platelet-dependent NETosis, rTM was added to the co-
culture of neutrophils and platelets. In the presence of
rTM (2, 10, or 50 μg/ml), LPS failed to induce NETosis.
Our results showed that rTM at 2 μg/ml was sufficient
to block LPS-induced NETosis (Fig. 1e). The results
showed that rTM inhibited the LPS-induced platelet-
dependent NETosis, as indicated by the unchanged
intracellular localization of DNA, MPO, and H2A.X
(Fig. 1e). On the other hand, rTM did not induce NETo-
sis in the absence of LPS (Fig. 1f ).
Quantification of NETosis in the co-culture of neutro-
phils and platelets revealed that the addition of LPS to
the neutrophil-platelet co-culture induced NETosis in
64 % of neutrophils (IQR, 36–82 %) (Fig. 2). However,
rTM at 2 μg/ml was sufficient to block LPS-induced
NETosis to 0 % (IQR, 0.0–0.03 %]) (p < 0.01 versus LPS
alone) (Fig. 2). Together, our findings demonstrate that
rTM is capable of suppressing NETosis in vitro.
Discussion
Our results showed that LPS stimulation did not induce
NETosis from neutrophils without co-culture with platelets.
These results are consistent with findings from a previous
study [2]. Importantly, our study revealed that LPS-induced
platelet-dependent NETosis was inhibited by rTM.
NETosis in the microvasculature is an important
molecular event causing endothelial dysfunction [2]. Our
data raise the possibility that endogenous TM both in
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Fig. 2 Quantification of inhibition of LPS-stimulated platelet-dependent
NETosis by rTM. Neutrophils and platelets were isolated from 11 healthy
adult volunteers and treated and stained as in Fig. 1. Quantification of
NETosis was performed by counting the numbers of neutrophils that
underwent NETosis and those of total neutrophils in the co-culture of
neutrophils and platelets. Neutrophil and platelet treatment groups
were control/untreated (n= 10), LPS alone (n= 10), LPS in the presence
of rTM (n= 10), and rTM alone (n= 3). Data are shown as the median
with interquartile range. Kruskal-Wallis one-way analysis of variance on
ranks (*p< 0.01 versus control and rTM treatment, n= 11 individuals)
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the endothelial cells and in the circulation (the soluble
form of TM) may decrease NETosis and thereby prevent
endothelial dysfunction contributing to the improve-
ments in the clinical outcome of patients with sepsis-
associated DIC.
Yipp et al. described two types of NETosis that occur
via two distinct pathways [11]. Phorbol 12-myristate 13-
acetate-induced NETosis is associated with nicotinamide
adenine dinucleotide phosphate oxidase-dependent cellular
death. This pathway requires hours for release of NETs. In
contrast, microbial exposure or LPS-induced NETosis
occurs rapidly (<30 min) [2, 12]. Moreover, the direct inter-
action of activated platelets with neutrophils causes NETo-
sis, particularly when platelets are activated via Toll-like
receptor (TLR) 4-mediated signaling [2]. Coagulopathy is
an integral component of the development of severe sepsis.
To investigate the effects of rTM on NETosis, we therefore
used the LPS-stimulated platelet-dependent NETosis, a
clinically relevant model of NETs in the context of coagu-
lopathy and sepsis.
As a limitation of these in vitro experiments, however,
the mechanisms of the rTM-mediated inhibition of
NETosis are not clear and remain to be determined. It is
possible that rTM may exert an inhibitory effect against
TLR4-mediated signaling. We are currently attempting
to clarify the mechanisms by which rTM inhibits LPS-
induced NETosis.
Our findings suggest that rTM and possibly endogen-
ous TM may have a novel role in the regulation of
NETosis. These data raise the possibility that the inhib-
ition of NETosis may contribute to the protective effects
of rTM in patients with sepsis and/or DIC. Further stud-
ies are required to determine whether rTM inhibits
NETosis in vivo in patients with sepsis and/or DIC.
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